首页> 外文期刊>Clinical Epidemiology >The right combination – treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg, South Africa
【24h】

The right combination – treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg, South Africa

机译:正确的组合–南非约翰内斯堡一家公共部门HIV诊所中开始一线固定剂量抗逆转录病毒治疗的HIV阳性患者的治疗结果

获取原文
       

摘要

Background: Long-term antiretroviral therapy (ART) adherence is critical for achieving optimal HIV treatment outcomes. Fixed-dose combination (FDC) single-pill regimens, introduced in South Africa in April 2013, has simplified pill taking. We evaluated treatment outcomes among patients initiated on a FDC compared to a similar multi-pill ART regimen in Johannesburg, South Africa. Methods: We conducted a retrospective cohort study of ART-na?ve HIV-positive non-pregnant adult (≥18 years) patients without tuberculosis who initiated first-line ART on tenofovir and emtricitabine or lamivudine with efavirenz at Themba Lethu Clinic in Johannesburg, South Africa. We compared those initiated on a multi-pill ART regimen (3–5 pills/day; September 1, 2011–August 31, 2012) to those initiated on a FDC ART regimen (one pill/day; September 1, 2013–August 31, 2014). Treatment outcomes included attrition (combination of lost to follow-up and mortality), missed medical visits, and virologic suppression (viral load <400 copies/mL) by 12 months post-ART initiation. Cox proportional hazards models and Poisson regression were used to estimate the association between FDCs vs multiple pills and treatment outcomes. Results: We included 3151 patients in our analysis; 2230 (70.8%) patients initiated multi-pill ART and 921 (29.2%) patients initiated on a FDC. By 12 months post-initiation, attrition (adjusted hazard ratio: 0.98; 95% CI: 0.77–1.24) was similar across regimen types (FDC vs multi-pill). Although not significant, patients on a FDC were marginally more likely to achieve viral suppression by 6 (adjusted relative rate [aRR]: 1.10; 95% CI: 0.99–1.23) and 12 months (aRR: 1.12; 95% CI: 0.92–1.36) on ART. Patients initiated on a FDC were significantly less likely to miss medical visits during the first 12 months of treatment (aRR: 0.66; 95% CI: 0.52–0.83). Conclusion: Our results suggest FDCs may have a role to play in supporting patient adherence and medical monitoring through improved medical visit attendance. This may potentially improve treatment outcomes later on in treatment.
机译:背景:长期坚持抗逆转录病毒疗法(ART)对于获得最佳HIV治疗效果至关重要。 2013年4月在南非推出的固定剂量组合(FDC)单丸方案简化了服用药丸的过程。与南非约翰内斯堡的类似多药ART方案相比,我们评估了FDC引发的患者的治疗效果。方法:我们对约翰内斯堡Themba Lethu诊所的替诺福韦和恩曲他滨或拉米夫定联合依非韦伦的一线抗病毒治疗,对未接受过ART免疫治疗的HIV阳性未怀孕成年人(≥18岁)进行了回顾性队列研究,南非。我们比较了采用多药抗逆转录病毒疗法(每天3至5片; 2011年9月1日至2012年8月31日)和采用FDC抗逆转录病毒抗逆转录病毒疗法(每天一粒; 2013年9月1日至8月31日) ,2014)。在开始治疗后12个月,治疗结局包括损耗(合并失访和死亡率),错过就诊以及病毒抑制(病毒载量<400份/ mL)。使用Cox比例风险模型和Poisson回归来估计FDC与多种药物之间的关联以及治疗效果。结果:我们纳入了3151例患者。 2230(70.8%)位患者开始了多药抗逆转录病毒疗法,而921(29.2%)位患者开始了FDC。在开始治疗后的12个月内,不同治疗方案类型(FDC与多药)的减员率(调整后的危险比:0.98; 95%CI:0.77-1.24)相似。尽管不显着,但接受FDC的患者在6个月(调整后的相对比率[aRR]:1.10; 95%CI:0.99–1.23)和12个月(aRR:1.12; 95%CI:0.92–9)上获得病毒抑制的可能性略高。 1.36)。在开始治疗的前12个月中,以FDC开始的患者错过医疗就诊的可能性大大降低(aRR:0.66; 95%CI:0.52-0.83)。结论:我们的结果表明,FDC可以通过改善就诊率来支持患者依从性和医疗监测。这可能会在以后的治疗中改善治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号